GeNeuro: encouraging results in multiple sclerosis – 10/28/2022 at 12:20

( – GeNeuro rose on the stock market this Friday following the presentation of phase 2 data confirming the potential of its temelimab in multiple sclerosis.

The biopharmaceutical company announced this morning that the primary analysis of this study – presented at the ECTRIMS congress in Amsterdam – showed an ‘excellent safety and tolerance profile’ at the highest doses.

The biomarker results further confirmed the synergistic potential to treat neurodegeneration with temelimab in addition to anti-inflammatory therapy.

As already announced, MRI biomarkers have also shown a favorable impact of temelimab in the preservation of neocortical anatomy and myelin integrity.

The phase 2 study, conducted at ASC Karolinska Institutet in Stockholm, involved a cohort of 42 patients treated with temelimab versus placebo for 48 weeks.

These individuals had confirmed disability progression without relapses after prior treatment with rituximab, an anti-CD20 drug that is very potent and effective against relapses and brain lesion formation.

Listed on the Paris Stock Exchange, the title rose 6.4% on Friday after these announcements.


Scroll to Top